{"meta":{"totalResults":1,"from":0},"results":[{"aliases":[{"type":"CodeName","name":"AZD4205"},{"type":"CodeName","name":"AZD 4205"},{"type":"CodeName","name":"AZD-4205"},{"type":"CASRegistryName","name":"2091134-68-6"},{"type":"Synonym","name":"JAK1 inhibitor AZD4205"}],"definition":{"html":"An orally available inhibitor of Janus-associated kinase 1 (JAK1), with potential antineoplastic activity. Upon oral administration, golidocitinib inhibits JAK-dependent signaling and may lead to an inhibition of cellular proliferation in JAK1-overexpressing tumor cells. The JAK-STAT (signal transducer and activator of transcription) signaling pathway is a major mediator of cytokine activity and is often dysregulated in a variety of tumor cell types. Additionally, JAK1 may be a primary driver of STAT3 phosphorylation and signaling, which plays a role in neoplastic transformation, resistance to apoptosis, tumor angiogenesis, metastasis, immune evasion, and treatment resistance.","text":"An orally available inhibitor of Janus-associated kinase 1 (JAK1), with potential antineoplastic activity. Upon oral administration, golidocitinib inhibits JAK-dependent signaling and may lead to an inhibition of cellular proliferation in JAK1-overexpressing tumor cells. The JAK-STAT (signal transducer and activator of transcription) signaling pathway is a major mediator of cytokine activity and is often dysregulated in a variety of tumor cell types. Additionally, JAK1 may be a primary driver of STAT3 phosphorylation and signaling, which plays a role in neoplastic transformation, resistance to apoptosis, tumor angiogenesis, metastasis, immune evasion, and treatment resistance."},"drugInfoSummaryLink":null,"nciConceptId":"C156774","nciConceptName":"Golidocitinib","termId":795786,"name":"golidocitinib","firstLetter":"g","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"golidocitinib"}],"links":null}